Overview

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

Phase:

Phase 2

Details

Lead Sponsor:

University of Pennsylvania

Collaborator:

Amgen

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin